Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fulgent Genetics, Inc. - Common Stock (NQ:FLGT)

21.98 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fulgent Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
FLGT Investors Have Opportunity to Join Fulgent Genetics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law Firm
Via Business Wire
FULGENT ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Fulgent Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.  - FLGT
From Pomerantz LLP
Via GlobeNewswire
A Peek at Fulgent Genetics's Future Earnings
 
Via Benzinga
Uncovering Potential: Fulgent Genetics's Earnings Preview
 
Via Benzinga
Fulgent Reports First Quarter 2025 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Earnings Scheduled For May 2, 2025
 
Via Benzinga
Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics Revenue Tops Estimates
Fulgent Genetics exceeded expectations in the fourth quarter of 2024, showcasing robust revenue growth and a GAAP loss. 
Via The Motley Fool
Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Earnings Scheduled For February 28, 2025
 
Via Benzinga
Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Reports Third Quarter 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Participate in Upcoming Conferences
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Reports Second Quarter 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
From Fulgent Pharma
Via Business Wire
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
From Fulgent Pharma
Via Business Wire
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
From Fulgent Pharma
Via Business Wire
FLGT Stock Earnings: Fulgent Genetics Beats EPS, Misses Revenue for Q1 2024
FLGT stock results show that Fulgent Genetics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Fulgent Reports First Quarter 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024
From Fulgent Genetics, Inc.
Via Business Wire
The 3 Best Digital Health Stocks for Personalized Medicine
Digital health stocks are becoming increasingly relevant as more and more people seek greater control over their health. 
Via InvestorPlace
Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting
From Fulgent Genetics, Inc.
Via Business Wire
Earnings Scheduled For November 3, 2023
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.